8-K - CRISPR Therapeutics AG (0001674416) (Filer)
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - CRISPR Therapeutics AG filed an 8-K with the SEC on Nov 2 (a notice of a material company event).
Directly affected
- CRSP CRISPR Therapeutics AG-12.2% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that CRISPR Therapeutics AG belongs to, so it often moves with news about it.
- BNTX BioNTech SE-9.6% 12d
BioNTech SE is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news.
- NBIX Neurocrine Biosciences
Neurocrine Biosciences is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news.
- QGEN Qiagen N.V
Qiagen N.V is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news.
- AMGN Amgen+17.8% 30d
Amgen is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.3% 30d
Gilead Sciences is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| CRSP | +3.04% | +8.60% | base | +0.08% | +3.64% | -2.87% | after close |
| XLV | -3.14% | -0.51% | base | -0.34% | +2.73% | +0.31% | after close |
| BNTX | -0.51% | +1.81% | base | -0.74% | +3.65% | -1.89% | after close |
| NBIX | +0.43% | +0.69% | base | +13.30% | +14.21% | +9.94% | after close |
| QGEN | -0.29% | +0.05% | base | +0.10% | +0.95% | +1.04% | after close |
| AMGN | -3.75% | -1.04% | base | -0.92% | +2.72% | -1.06% | after close |
| GILD | -6.65% | -2.82% | base | -1.70% | +2.38% | -1.69% | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-02 AccNo: 0001193125-26-443644 Size: 423 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
How far CRISPR Therapeutics AG (CRSP) has moved since 2 Nov 2026
Since the first closing price after “8-K - CRISPR Therapeutics AG (0001674416) (Filer),” CRISPR Therapeutics AG (CRSP) is +3.61%.
| Company | When | Move | Status |
|---|---|---|---|
| Amgen (AMGN) | that day | -0.92% | final price |
| Amgen (AMGN) | the next day | +2.72% | final price |
| Amgen (AMGN) | two days later | -1.06% | final price |
| Amgen (AMGN) | three days earlier | -1.04% | final price |
| Amgen (AMGN) | five days earlier | -3.75% | final price |
| BioNTech SE (BNTX) | that day | -0.74% | final price |
| BioNTech SE (BNTX) | the next day | +3.65% | final price |
| BioNTech SE (BNTX) | two days later | -1.89% | final price |
| BioNTech SE (BNTX) | three days earlier | +1.81% | final price |
| BioNTech SE (BNTX) | five days earlier | -0.51% | final price |
| CRISPR Therapeutics AG (CRSP) | that day | +0.08% | final price |
| CRISPR Therapeutics AG (CRSP) | the next day | +3.64% | final price |
| CRISPR Therapeutics AG (CRSP) | two days later | -2.87% | final price |
| CRISPR Therapeutics AG (CRSP) | three days earlier | +8.60% | final price |
| CRISPR Therapeutics AG (CRSP) | five days earlier | +3.04% | final price |
| Gilead Sciences (GILD) | that day | -1.70% | final price |
| Gilead Sciences (GILD) | the next day | +2.38% | final price |
| Gilead Sciences (GILD) | two days later | -1.69% | final price |
| Gilead Sciences (GILD) | three days earlier | -2.82% | final price |
| Gilead Sciences (GILD) | five days earlier | -6.65% | final price |
| Neurocrine Biosciences (NBIX) | that day | +13.30% | final price |
| Neurocrine Biosciences (NBIX) | the next day | +14.21% | final price |
| Neurocrine Biosciences (NBIX) | two days later | +9.94% | final price |
| Neurocrine Biosciences (NBIX) | three days earlier | +0.69% | final price |
| Neurocrine Biosciences (NBIX) | five days earlier | +0.43% | final price |
| Qiagen N.V (QGEN) | that day | +0.10% | final price |
| Qiagen N.V (QGEN) | the next day | +0.95% | final price |
| Qiagen N.V (QGEN) | two days later | +1.04% | final price |
| Qiagen N.V (QGEN) | three days earlier | +0.05% | final price |
| Qiagen N.V (QGEN) | five days earlier | -0.29% | final price |
| Select Sector Spdr Tr (XLV) | that day | -0.34% | final price |
| Select Sector Spdr Tr (XLV) | the next day | +2.73% | final price |
| Select Sector Spdr Tr (XLV) | two days later | +0.31% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.51% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -3.14% | final price |
Congressional trades in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 41 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 68 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 82 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 84 days before publication. Filed 4 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around CRISPR Therapeutics AG (CRSP)
Companies carried with this story
- CRSP CRISPR Therapeutics AG
In “8-K - CRISPR Therapeutics AG (0001674416) (Filer),” CRISPR Therapeutics AG (CRSP) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> CRSP
- XLV Select Sector Spdr Tr
In “8-K - CRISPR Therapeutics AG (0001674416) (Filer),” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR holds the health sector that CRISPR Therapeutics AG belongs to, so it often moves with news about it
- BNTX BioNTech SE
BioNTech SE (BNTX) is linked, with no stored direction, medium confidence in the 2 Nov 2026 story “8-K - CRISPR Therapeutics AG (0001674416) (Filer).” Reason on file: BioNTech SE is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news
- NBIX Neurocrine Biosciences
For “8-K - CRISPR Therapeutics AG (0001674416) (Filer),” Neurocrine Biosciences (NBIX) is linked, with no stored direction, medium confidence. Reason on file: Neurocrine Biosciences is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news
- QGEN Qiagen N.V
In “8-K - CRISPR Therapeutics AG (0001674416) (Filer),” Qiagen N.V (QGEN) is linked, with no stored direction, medium confidence. Reason on file: Qiagen N.V is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news
- AMGN Amgen
For “8-K - CRISPR Therapeutics AG (0001674416) (Filer),” Amgen (AMGN) is linked, with no stored direction, medium confidence. Reason on file: Amgen is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news
- GILD Gilead Sciences
Gilead Sciences (GILD) is linked, with no stored direction, medium confidence in the 2 Nov 2026 story “8-K - CRISPR Therapeutics AG (0001674416) (Filer).” Reason on file: Gilead Sciences is a peer of CRISPR Therapeutics AG in biological products, (no diagnostic substances); rivals often move on the same news
How “8-K - CRISPR Therapeutics AG (0001674416) (Filer)” reaches CRISPR Therapeutics AG (CRSP)
On 2 Nov 2026, “8-K - CRISPR Therapeutics AG (0001674416) (Filer)” is the story that connects CRISPR Therapeutics AG (CRSP) to this story.
For CRISPR Therapeutics AG (CRSP), the reason on file says SEC 8-K filing -> direct issuer disclosure -> CRSP
A second company, Select Sector Spdr Tr (XLV), is listed for a different reason: Health Care Select Sector SPDR holds the health sector that CRISPR Therapeutics AG belongs to, so it often moves with news about it
Dates and price levels for CRISPR Therapeutics AG (CRSP)
BNTX traded between 85.88 and 102.23 across 11 sessions. The latest close on file is 86.92. CRSP traded between 47.44 and 60.74 across 20 sessions. The latest close on file is 51.79.
A simple score for CRISPR Therapeutics AG (CRSP)
46 out of 100
“8-K - CRISPR Therapeutics AG (0001674416) (Filer)” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.